John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, discusses global and national initiatives for the development of new antibiotics.
Interview Transcript (slightly modified for readability)
“There’s a lot of movement at the global level for the development of new antibiotics, from the World Health Organization, to the Centers for Disease Control and Prevention, and recognition that we certainly have a problem that needs to be fixed. It truly is a market failure for why these new, life-saving drugs aren’t being developed. There are incentives that are being proposed in order to attempt to try to reinvigorate the antibiotic pipeline.
There are in general two categories, either a push incentive, to provide reasons for companies to get back in the space, or pull incentives in order to pull the drug through and establish a market for those therapies. A recent report came out from Jim O’Neill, [which] outlined additional steps in order to improve the antibiotic pipeline. Additionally, there’s legislation that’s being passed in the United States, the GAIN Act, as well as other pending legislation, such as the DISARM act, the PATH act, and the READI act, which would all provide additional types of incentives in order to promote the development of new antimicrobials.
A lot of work is being done at the global level, and more needs to be done in order to ensure that we have access to these life-saving drugs.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Influenza A (H3N2) has caused most of the illnesses in this severe flu season, but influenza B is becoming increasingly responsible for more infections as the flu season continues to hit the United States.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512